
Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …
Boehringer Ingelheim’s hepatitis C candidate faldaprevir has moved a potential step closer to market with the news that the European …

